Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in thrombolytic therapy.

S F Badylak1, J Henkin, S E Burke

  • 1Hillenbrand Biomedical Engineering Center, Purdue University, West Lafayette, Indiana 47907.

Advances in Pharmacology (San Diego, Calif.)
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Matrix-bound nanovesicle-associated IL-33 supports functional recovery after skeletal muscle injury by initiating a pro-regenerative macrophage phenotypic transition.

NPJ Regenerative medicine·2024
Same author

Menisco-fibular ligament - an overview: cadaveric dissection, clinical and magnetic resonance imaging diagnosis, arthroscopic visualisation and treatment.

Folia morphologica·2020
Same author

Factors influencing medical student self-competence to provide weight management services.

Clinical obesity·2018
Same author

Seminars in Immunology Special Issue Foreword.

Seminars in immunology·2017
Same author

Mechanical strength vs. degradation of a biologically-derived surgical mesh over time in a rodent full thickness abdominal wall defect.

Biomaterials·2016
Same author

Fractionation of an ECM hydrogel into structural and soluble components reveals distinctive roles in regulating macrophage behavior.

Biomaterials science·2016
Same journal

Preface.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides: From permeability assay toolbox to data-driven discovery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from phage display.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Physiological strategies for brain delivery.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

Brain shuttle peptides derived from natural proteins.

Advances in pharmacology (San Diego, Calif.)·2026
Same journal

In vitro blood-brain barrier models for the study of brain shuttle peptide transport.

Advances in pharmacology (San Diego, Calif.)·2026
See all related articles

New strategies enhance plasminogen activator therapy for dissolving blood clots, aiming to improve efficacy and reduce bleeding risks. Further human trials are needed to confirm these promising findings for treating thrombosis.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Thrombosis Research

Background:

  • Pharmacologic lysis of thrombi is a key treatment for ischemia.
  • Existing plasminogen activators face challenges with efficacy and hemorrhage risk.
  • Minimizing rethrombosis after lysis is crucial for treatment success.

Purpose of the Study:

  • To explore novel strategies for enhancing plasminogen activator therapy.
  • To investigate methods for increasing thrombolytic efficacy.
  • To reduce the incidence of hemorrhage and rethrombosis.

Main Methods:

  • Development of thrombus-directed antibodies linked to plasminogen activators.
  • Increasing plasminogen concentration at the thrombus site.
  • Utilizing anticoagulant and antiplatelet therapies.

Related Experiment Videos

  • Employing combination plasminogen activator therapy.

    • Main Results:

    • Strategies tested in vitro and in animal models show promise.
    • Methods aim to improve clot dissolution and minimize adverse events.
    • Extrapolation to human patients requires further controlled trials.

    Conclusions:

    • Novel strategies for plasminogen activator therapy are under development.
    • These approaches target enhanced efficacy and safety in treating thrombosis.
    • Findings provide a basis for future human clinical trials.